Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dostarlimab Monotherapy in Untreated Stage II/III dMMR/MSI-H Locally Advanced Rectal Cancer (China)
CTR20243096Phase 2Active
- Sponsor
- GSK
- Start
- Nov 2024
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of dostarlimab in rectal adenocarcinoma, sponsored by GSK. Started Nov 2024; status: active.
02
Drugs
dostarlimab
03
Conditions
rectal adenocarcinoma
Beyond the preview
Go deeper on CTR20243096.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20243096.